Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProGEL-AB (Progel Adhesion Barrier) is a resorbable hydrogel medical device designed to prevent post-operative adhesions following abdominal or pelvic surgical procedures. Developed by Neomend (now part of Becton Dickinson), the product consists of a proprietary formulation of polyethylene glycol (PEG) and human serum albumin (HSA). When applied via spray, these components cross-link to form a flexible, adherent hydrogel matrix that acts as a physical barrier between visceral organs and the peritoneal wall. The hydrogel is eventually resorbed by the body after the critical healing period. It is intended for use in both open and laparoscopic surgeries and received CE Mark approval in 2011.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ProGEL-AB.